LP-184 enhances PD1 block by reshaping tumor microenvironment
Aug. 12, 2024
Lantern Pharma Inc. has presented new data on their novel acylfulvene compound LP-184 as a DNA-damaging agent that induces DNA double-strand breaks (DNA DSBs) in cancer cells and may activate immune responses by activation of the cGAS/STING pathway.